{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T08:10:28Z","timestamp":1758874228625,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81600135"],"award-info":[{"award-number":["81600135"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of\u00a0Hunan Province","doi-asserted-by":"publisher","award":["2021JJ41011"],"award-info":[{"award-number":["2021JJ41011"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-SY2021QN-0010"],"award-info":[{"award-number":["Y-SY2021QN-0010"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s10637-022-01313-8","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T08:06:26Z","timestamp":1666771586000},"page":"1231-1243","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tetra-arsenic tetra-sulfide enhances NK-92MI mediated cellular immunotherapy in all-trans retinoic acid-resistant acute promyelocytic leukemia"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2610-3652","authenticated-orcid":false,"given":"Yanfeng","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1048-9842","authenticated-orcid":false,"given":"Yan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2368-5703","authenticated-orcid":false,"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9893-9918","authenticated-orcid":false,"given":"Xuefeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,26]]},"reference":[{"issue":"3","key":"1313_CR1","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3390\/cancers12030624","volume":"12","author":"A Liquori","year":"2020","unstructured":"Liquori A, Ibanez M, Sargas C et al (2020) Acute promyelocytic leukemia: a constellation of molecular events around a single PML-RARA fusion gene. Cancers (Basel) 12(3):624","journal-title":"Cancers (Basel)"},{"issue":"6","key":"1313_CR2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41408-021-00514-3","volume":"11","author":"M Yilmaz","year":"2021","unstructured":"Yilmaz M, Kantarjian H, Ravandi F (2021) Acute promyelocytic leukemia current treatment algorithms. Blood Cancer J 11(6):123","journal-title":"Blood Cancer J"},{"issue":"4","key":"1313_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.25","volume":"5","author":"CC Coombs","year":"2015","unstructured":"Coombs CC, Tavakkoli M, Tallman MS (2015) Acute promyelocytic leukemia: where did we start, where are we now, and the future. Blood Cancer J 5(4):e304","journal-title":"Blood Cancer J"},{"issue":"4","key":"1313_CR4","doi-asserted-by":"publisher","first-page":"142","DOI":"10.2991\/chi.k.210703.001","volume":"3","author":"MA Sanz","year":"2021","unstructured":"Sanz MA, Barrag\u00e1n E (2021) History of acute promyelocytic leukemia. Clin Hematol Int 3(4):142\u2013152","journal-title":"Clin Hematol Int"},{"issue":"1","key":"1313_CR5","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1038\/s41467-018-04384-5","volume":"9","author":"J Lehmann-Che","year":"2018","unstructured":"Lehmann-Che J, Bally C, Letouze E et al (2018) Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia. Nat Commun 9(1):2047","journal-title":"Nat Commun"},{"issue":"6","key":"1313_CR6","doi-asserted-by":"publisher","first-page":"e222","DOI":"10.3324\/haematol.2016.162206","volume":"102","author":"A Fasan","year":"2017","unstructured":"Fasan A, Haferlach C, Perglerova K et al (2017) Molecular landscape of acute promyelocytic leukemia at diagnosis and relapse. Haematologica 102(6):e222\u2013e224","journal-title":"Haematologica"},{"issue":"5","key":"1313_CR7","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nrc.2018.10","volume":"18","author":"Y Shono","year":"2018","unstructured":"Shono Y, van den Brink MRM (2018) Gut microbiota injury in allogeneic haematopoietic stem cell transplantation. Nat Rev Cancer 18(5):283\u2013295","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1313_CR8","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s13046-019-1266-0","volume":"38","author":"S Kruger","year":"2019","unstructured":"Kruger S, Ilmer M, Kobold S et al (2019) Advances in cancer immunotherapy 2019\u2013latest trends. J Exp Clin Cancer Res 38(1):268","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"1313_CR9","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00262-016-1792-y","volume":"65","author":"PS Becker","year":"2016","unstructured":"Becker PS, Suck G, Nowakowska P et al (2016) Selection and expansion of natural killer cells for NK cell-based immunotherapy. Cancer Immunol Immunother 65(4):477\u2013484","journal-title":"Cancer Immunol Immunother"},{"key":"1313_CR10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.exphem.2016.10.003","volume":"46","author":"J Ayello","year":"2017","unstructured":"Ayello J, Hochberg J, Flower A et al (2017) Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: Potential for adoptive cellular immunotherapy. Exp Hematol 46:38\u201347","journal-title":"Exp Hematol"},{"key":"1313_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fimmu.2016.00091","volume":"7","author":"H Klingemann","year":"2016","unstructured":"Klingemann H, Boissel L, Toneguzzo F (2016) Natural killer cells for immunotherapy- advantages of the NK-92 cell line over blood NK cells. Front Immunol 7:91","journal-title":"Front Immunol"},{"key":"1313_CR12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.clim.2018.04.006","volume":"192","author":"H Meng","year":"2018","unstructured":"Meng H, Sun X, Song Y et al (2018) La\/SSB chimeric autoantibody receptor modified NK92MI cells for targeted therapy of autoimmune disease. Clin Immunol 192:40\u201349","journal-title":"Clin Immunol"},{"issue":"5","key":"1313_CR13","first-page":"1374","volume":"27","author":"YF Liu","year":"2019","unstructured":"Liu YF, Jia Y, He PC et al (2019) Influence of oridonin on the icilling acitivity of NK-92 MI cells targeting cell THP1 and its mechanism. Zhongguo Shi Yan Xue Ye Xue Za Zhi 27(5):1374\u20131379","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"5","key":"1313_CR14","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1097\/CJI.0b013e3181755deb","volume":"31","author":"JY Kim","year":"2008","unstructured":"Kim JY, Bae JH, Lee SH et al (2008) Induction of NKG2D ligands and subsequent enhancement of NK cell-mediated lysis of cancer cells by arsenic trioxide. J Immunother 31(5):475\u2013486","journal-title":"J Immunother"},{"key":"1313_CR15","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.2147\/DDDT.S305244","volume":"15","author":"L Zhang","year":"2021","unstructured":"Zhang L, Yang XM, Chen J et al (2021) Population pharmacokinetics and safety of oral tetra-arsenic tetra-sulfide formula in pediatric acute promyelocytic leukemia. Drug Des Devel Ther 15:1633\u20131640","journal-title":"Drug Des Devel Ther"},{"issue":"11","key":"1313_CR16","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/j.leukres.2010.03.038","volume":"34","author":"J Qi","year":"2010","unstructured":"Qi J, He P, Chen W et al (2010) Comparative proteome study of apoptosis induced by As4S4 in retinoid acid resistant human acute promyelocytic leukemia NB4-R1 cells. Leuk Res 34(11):1506\u20131516","journal-title":"Leuk Res"},{"issue":"1","key":"1313_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-019-0956-8","volume":"18","author":"S Duan","year":"2019","unstructured":"Duan S, Guo W, Xu Z et al (2019) Natural killer group 2D receptor and its ligands in cancer immune escape. Mol Cancer 18(1):1\u201314","journal-title":"Mol Cancer"},{"issue":"9244","key":"1313_CR18","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/S0140-6736(00)03231-1","volume":"356","author":"K Imai","year":"2000","unstructured":"Imai K, Matsuyama S, Miyake S et al (2000) Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 356(9244):1795\u20131799","journal-title":"Lancet"},{"issue":"2","key":"1313_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.54319\/jjbs\/150207","volume":"15","author":"ND Lestari","year":"2022","unstructured":"Lestari ND, Rahmah AC, Adharini WI et al (2022) Bioactivity of moringa oleifera and albumin formulation in controlling TNF-\u03b1 and lFN-\u03b3 production by NK cells in mice model type 1 diabetes. Jordan J Biol Sci 15(2):205\u2013208","journal-title":"Jordan J Biol Sci"},{"issue":"10","key":"1313_CR20","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.3390\/cancers11101591","volume":"11","author":"NI Noguera","year":"2019","unstructured":"Noguera NI, Catalano G, Banella C et al (2019) Acute promyelocytic leukemia: update on the mechanisms of leukemogenesis, resistance and on innovative treatment strategies. Cancers (Basel) 11(10):1591","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1313_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/14656566.2021.1961744","volume":"23","author":"F Ferrara","year":"2022","unstructured":"Ferrara F, Molica M, Bernardi M (2022) Drug treatment options for acute promyelocytic leukemia. Expert Opin Pharmacother 23(1):117\u2013127","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"1313_CR22","first-page":"64","volume":"9","author":"F You","year":"2019","unstructured":"You F, Wang Y, Jiang L et al (2019) A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia. Am J Cancer Res 9(1):64\u201378","journal-title":"Am J Cancer Res"},{"key":"1313_CR23","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3389\/fphar.2019.00326","volume":"10","author":"C Yang","year":"2019","unstructured":"Yang C, Du M, Yan F et al (2019) Focused ultrasound improves NK-92MI cells infiltration into tumors. Front Pharmacol 10:326","journal-title":"Front Pharmacol"},{"issue":"7","key":"1313_CR24","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1158\/2326-6066.CIR-18-0500","volume":"7","author":"J Cursons","year":"2019","unstructured":"Cursons J, Souza-Fonseca-Guimaraes F, Foroutan M et al (2019) A gene signature predicting natural killer cell infiltration and improved survival in melanoma patients. Cancer Immunol Res 7(7):1162\u20131174","journal-title":"Cancer Immunol Res"},{"key":"1313_CR25","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3389\/fimmu.2020.00060","volume":"11","author":"C Zhang","year":"2020","unstructured":"Zhang C, Hu Y, Shi CD (2020) Targeting natural killer cells for tumor immunotherapy. Front Immunol 11:60","journal-title":"Front Immunol"},{"key":"1313_CR26","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.3389\/fimmu.2019.03038","volume":"10","author":"O Melaiu","year":"2020","unstructured":"Melaiu O, Lucarini V, Cifaldi L et al (2020) Influence of the tumor microenvironment on NK cell function in solid tumors. Front Immunol 10:3038","journal-title":"Front Immunol"},{"issue":"4","key":"1313_CR27","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s12185-016-2148-2","volume":"105","author":"T Tochigi","year":"2017","unstructured":"Tochigi T, Aoki T, Kikushige Y et al (2017) Mobilization of human immature hematopoietic progenitors through combinatory use of bortezomib and immunomodulatory drugs. Int J Hematol 105(4):423\u2013432","journal-title":"Int J Hematol"},{"issue":"11","key":"1313_CR28","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1007\/s00262-019-02411-y","volume":"68","author":"C Lapenta","year":"2019","unstructured":"Lapenta C, Donati S, Spadaro F et al (2019) Lenalidomide improves the therapeutic effect of an interferon-alpha-dendritic cell-based lymphoma vaccine. Cancer Immunol Immunother 68(11):1791\u20131804","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"1313_CR29","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1002\/jbm.a.37387","volume":"110","author":"EJ Comparetti","year":"2022","unstructured":"Comparetti EJ, Lins PMP, Quitiba J et al (2022) Cancer cell membrane-derived nanoparticles block the expression of immune checkpoint proteins on cancer cells and coordinate modulatory activity on immunosuppressive macrophages. J Biomed Mater Res A 110(8):1499\u20131511","journal-title":"J Biomed Mater Res A"},{"issue":"5","key":"1313_CR30","first-page":"6267","volume":"16","author":"L Zhong","year":"2018","unstructured":"Zhong L, Xu F, Chen F (2018) Arsenic trioxide induces the apoptosis and decreases NF-kappaB expression in lymphoma cell lines. Oncol Lett 16(5):6267\u20136274","journal-title":"Oncol Lett"},{"key":"1313_CR31","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.toxlet.2017.05.005","volume":"275","author":"A Bahari","year":"2017","unstructured":"Bahari A, Salmani V (2017) Environmentally relevant dose of arsenic interferes in functions of human monocytes derived dendritic cells. Toxicol Lett 275:118\u2013122","journal-title":"Toxicol Lett"},{"issue":"15","key":"1313_CR32","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.3390\/ijerph16152746","volume":"16","author":"HW Huang","year":"2019","unstructured":"Huang HW, Lee CH, Yu HS (2019) Arsenic-induced carcinogenesis and immune dysregulation. Int J Environ Res Public Health 16(15):2746","journal-title":"Int J Environ Res Public Health"},{"key":"1313_CR33","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.1182\/blood-2018-99-117795","volume":"132","author":"X Zhang","year":"2018","unstructured":"Zhang X, Yang J, Fanyong LV et al (2018) A long-term retrospective analysis of arsenic-containing triple-agents treatment for acute promyelocytic leukemia (APL) in a cohort from a single hospital. Blood 132:4060","journal-title":"Blood"},{"issue":"4","key":"1313_CR34","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1182\/blood-2003-01-0019","volume":"102","author":"HR Salih","year":"2003","unstructured":"Salih HR, Antropius H, Gieseke F et al (2003) Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 102(4):1389\u20131396","journal-title":"Blood"},{"issue":"1","key":"1313_CR35","doi-asserted-by":"publisher","first-page":"37","DOI":"10.29245\/2578-3009\/2018\/1.1115","volume":"2","author":"FS Basingab","year":"2018","unstructured":"Basingab FS, Morgan DJ (2018) ICAM-1 overexpression counteracts immune-suppression by tumour cell-derived PGE2 to restore CTL function. J Immunol Sci 2(1):37\u201345","journal-title":"J Immunol Sci"},{"key":"1313_CR36","doi-asserted-by":"publisher","first-page":"18815","DOI":"10.1038\/srep18815","volume":"6","author":"YC Chen","year":"2016","unstructured":"Chen YC, Statt S, Wu R et al (2016) High mobility group box 1-induced epithelial mesenchymal transition in human airway epithelial cells. Sci Rep 6:18815","journal-title":"Sci Rep"},{"issue":"9","key":"1313_CR37","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.3390\/jcm11092277","volume":"11","author":"IF van Luijk","year":"2022","unstructured":"van Luijk IF, Smith SM, Marte Ojeda MC et al (2022) A review of the effects of cervical cancer standard treatment on immune parameters in peripheral blood, tumor draining lymph nodes, and local tumor microenvironment. J Clin Med 11(9):2277","journal-title":"J Clin Med"},{"issue":"1","key":"1313_CR38","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","volume":"13","author":"M Obeid","year":"2007","unstructured":"Obeid M, Tesniere A, Ghiringhelli F, Fimia GM et al (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13(1):54\u201361","journal-title":"Nat Med"},{"issue":"10","key":"1313_CR39","doi-asserted-by":"publisher","first-page":"16824","DOI":"10.1002\/jcp.28358","volume":"234","author":"A Salmaninejad","year":"2019","unstructured":"Salmaninejad A, Valilou SF, Shabgah AG et al (2019) PD-1\/PD-L1 pathway: Basic biology and role in cancer immunotherapy. J Cell Physiol 234(10):16824\u201316837","journal-title":"J Cell Physiol"},{"key":"1313_CR40","doi-asserted-by":"publisher","first-page":"5973","DOI":"10.2147\/OTT.S135157","volume":"11","author":"DD Stenehjem","year":"2018","unstructured":"Stenehjem DD, Tran D, Nkrumah MA et al (2018) PD1\/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer. Onco Targets Ther 11:5973\u20135989","journal-title":"Onco Targets Ther"},{"issue":"1","key":"1313_CR41","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00277-017-3127-2","volume":"97","author":"TSY Chan","year":"2018","unstructured":"Chan TSY, Li J, Loong F et al (2018) PD1 blockade with low-dose nivolumab in NK\/T cell lymphoma failing L-asparaginase: efficacy and safety. Ann Hematol 97(1):193\u2013196","journal-title":"Ann Hematol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-022-01313-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-022-01313-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-022-01313-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:53:44Z","timestamp":1678510424000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-022-01313-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,26]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1313"],"URL":"https:\/\/doi.org\/10.1007\/s10637-022-01313-8","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"type":"print","value":"0167-6997"},{"type":"electronic","value":"1573-0646"}],"subject":[],"published":{"date-parts":[[2022,10,26]]},"assertion":[{"value":"16 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal experiment protocol was reviewed and approved by the Ethics Committee of Xiangya Hospital of Central South University (protocol no. 201603064).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent\u00a0to publish"}},{"value":"None.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}